These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 17419693)

  • 41. Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants.
    Hoyt R; Ritchie DS; Roberts AW; Macgregor L; Curtis DJ; Szer J; Grigg AP
    Bone Marrow Transplant; 2008 Apr; 41(7):651-8. PubMed ID: 18176619
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation.
    Lutz C; Massenkeil G; Nagy M; Neuburger S; Tamm I; Rosen O; Dörken B; Arnold R
    Bone Marrow Transplant; 2008 May; 41(9):805-12. PubMed ID: 18195682
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Titrating graft-versus-host disease: is it worth a try?
    Akpek G
    Bone Marrow Transplant; 2006 Nov; 38(10):653-6. PubMed ID: 17006455
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD.
    Guo M; Sun Z; Sun QY; Han Q; Yu CL; Wang DH; Qiao JH; Chen B; Sun WJ; Hu KX; Liu GX; Liu B; Zhao RC; Ai H
    Biol Blood Marrow Transplant; 2009 Aug; 15(8):930-7. PubMed ID: 19589482
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen.
    Dey BR; Shaffer J; Yee AJ; McAfee S; Caron M; Power K; Ting DT; Colby C; Preffer F; Ballen K; Attar E; Saidman S; Tarbell N; Sachs D; Sykes M; Spitzer TR
    Bone Marrow Transplant; 2007 Jul; 40(1):19-27. PubMed ID: 17468773
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preventive effect of ultraviolet radiation on murine chronic sclerodermatous graft-versus-host disease.
    Mermet I; Kleinclauss F; Marandin A; Guérrini JS; Angonin R; Tiberghien P; Saas P; Aubin F
    Transplantation; 2007 Dec; 84(12):1696-700. PubMed ID: 18165783
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Modulating graft-versus-host disease to enhance the graft-versus-leukemia effect.
    Alyea EP
    Best Pract Res Clin Haematol; 2008 Jun; 21(2):239-50. PubMed ID: 18503989
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diabetes with partial lipodystrophy following sclerodermatous chronic graft vs. host disease.
    Rooney DP; Ryan MF
    Diabet Med; 2006 Apr; 23(4):436-40. PubMed ID: 16620274
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
    Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
    Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The graft content of donor T cells expressing gamma delta TCR+ and CD4+foxp3+ predicts the risk of acute graft versus host disease after transplantation of allogeneic peripheral blood stem cells from unrelated donors.
    Pabst C; Schirutschke H; Ehninger G; Bornhäuser M; Platzbecker U
    Clin Cancer Res; 2007 May; 13(10):2916-22. PubMed ID: 17504991
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dynamics in chimerism of T cells and dendritic cells in relapsed CML patients and the influence on the induction of alloreactivity following donor lymphocyte infusion.
    Levenga H; Woestenenk R; Schattenberg AV; Maas F; Jansen JH; Raymakers R; De Mulder PH; van de Wiel-van Kemenade E; Schaap N; de Witte T; Dolstra H
    Bone Marrow Transplant; 2007 Sep; 40(6):585-92. PubMed ID: 17637687
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
    You Y; Li QB; Chen ZC; Li WM; Xia LH; Zhou H; Zou P
    Chin Med J (Engl); 2008 Sep; 121(18):1770-4. PubMed ID: 19080355
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning.
    Grigg AP; Gibson J; Bardy PG; Reynolds J; Shuttleworth P; Koelmeyer RL; Szer J; Roberts AW; To LB; Kennedy G; Bradstock KF
    Biol Blood Marrow Transplant; 2007 May; 13(5):560-7. PubMed ID: 17448915
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies.
    Ozdemir E; Saliba RM; Champlin RE; Couriel DR; Giralt SA; de Lima M; Khouri IF; Hosing C; Kornblau SM; Anderlini P; Shpall EJ; Qazilbash MH; Molldrem JJ; Chemaly RF; Komanduri KV
    Bone Marrow Transplant; 2007 Jul; 40(2):125-36. PubMed ID: 17530009
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Graft-versus-adult T-cell leukemia/lymphoma effect following allogeneic hematopoietic stem cell transplantation.
    Yonekura K; Utsunomiya A; Takatsuka Y; Takeuchi S; Tashiro Y; Kanzaki T; Kanekura T
    Bone Marrow Transplant; 2008 Jun; 41(12):1029-35. PubMed ID: 18332910
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Activated circulating dendritic cells after hematopoietic stem cell transplantation predict acute graft-versus-host disease.
    Lau J; Sartor M; Bradstock KF; Vuckovic S; Munster DJ; Hart DN
    Transplantation; 2007 Apr; 83(7):839-46. PubMed ID: 17460553
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cutaneous graft-versus-host disease: a guide for the dermatologist.
    Häusermann P; Walter RB; Halter J; Biedermann BC; Tichelli A; Itin P; Gratwohl A
    Dermatology; 2008; 216(4):287-304. PubMed ID: 18230976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.